Science Explorer Back to mapMap
Discussion
Research facility · San Antonio · United States

South Texas Accelerated Research Therapeutics

In research, South Texas Accelerated Research Therapeutics stands highest in Health Sciences (#10,523 of 16,688 worldwide) and Medicine (#10,714 of 14,558 worldwide), over all time.

World rank, 2022-now
#22,084
of 22,385 · #26,975 all time
Rank in United States
#3,282
of 3,332
Research works
273
▲ 9% vs 2018-21
Citations
6.9k
25.4 per fractional work
Top-10% rate
14.7%
all institutions 10.0%
vs its own fields
0.97×
1.00× is exactly expected
Open access
29%
world 40%
International
35%
world 18%
South Texas Accelerated Research Therapeutics

What is South Texas Accelerated Research Therapeutics known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Health SciencesDomain #10,523 of 16,688 20.0%160
MedicineField #10,714 of 14,558 20.1%158

Each strip is that field's whole ranked pool, with the notch where South Texas Accelerated Research Therapeutics sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does South Texas Accelerated Research Therapeutics work in?

In 2022-now, 61% of research at South Texas Accelerated Research Therapeutics is in Health Sciences, 29% in Life Sciences. Its largest fields are Medicine (60%), Biochemistry, Genetics and Molecular Biology (21%), Immunology and Microbiology (7%). It does 2.4× the world's share of Health Sciences.

Health Sciences: 48 fractional works · 61.3% of its workMedicine: 47 fractional works · 60.4% of its workOncology: 20 fractional works · 25.2% of its workPulmonary and Respiratory Medicine: 10 fractional works · 12.9% of its workRadiology, Nuclear Medicine and Imaging: 6 fractional works · 7.3% of its workSurgery: 2 fractional works · 2.1% of its workRheumatology: 1 fractional works · 1.9% of its workGenetics: 1 fractional works · 1.6% of its workPathology and Forensic Medicine: 1 fractional works · 1.6% of its workHematology: 1 fractional works · 1.1% of its workEpidemiology: 1 fractional works · 1.0% of its workReproductive Medicine: 1 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.6% of its workNeurology: 0 fractional works · 0.6% of its workPharmacology: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.5% of its workImmunology and Allergy: 0 fractional works · 0.5% of its workPhysiology: 0 fractional works · 0.4% of its workInfectious Diseases: 0 fractional works · 0.4% of its workEmergency Medicine: 0 fractional works · 0.2% of its workObstetrics and Gynecology: 0 fractional works · 0.2% of its workOphthalmology: 0 fractional works · 0.2% of its workHepatology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.5% of its workHealth Professions: 1 fractional works · 0.8% of its workGeneral Health Professions: 0 fractional works · 0.3% of its workEmergency Medical Services: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 0.1% of its workDentistry: 0 fractional works · 0.0% of its workLife Sciences: 23 fractional works · 29.1% of its workBiochemistry, Genetics and Molecular Biology: 16 fractional works · 21.0% of its workMolecular Biology: 9 fractional works · 11.3% of its workCancer Research: 4 fractional works · 5.4% of its workBiotechnology: 2 fractional works · 2.5% of its workGenetics: 1 fractional works · 1.4% of its workCell Biology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 5 fractional works · 6.6% of its workImmunology: 5 fractional works · 6.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workAgricultural and Biological Sciences: 1 fractional works · 0.7% of its workNeuroscience: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.3% of its workPhysical Sciences: 4 fractional works · 5.0% of its workEngineering: 2 fractional works · 2.4% of its workAerospace Engineering: 2 fractional works · 2.1% of its workBiomedical Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workPhysics and Astronomy: 1 fractional works · 1.3% of its workAstronomy and Astrophysics: 1 fractional works · 1.1% of its workRadiation: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.0% of its workComputer Science: 0 fractional works · 0.5% of its workComputational Theory and Mathematics: 0 fractional works · 0.5% of its workMaterials Science: 0 fractional works · 0.4% of its workBiomaterials: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workChemistry: 0 fractional works · 0.2% of its workMathematics: 0 fractional works · 0.1% of its workEnvironmental Science: 0 fractional works · 0.1% of its workSocial Sciences: 4 fractional works · 4.6% of its workSocial Sciences: 2 fractional works · 2.1% of its workGender Studies: 0 fractional works · 0.6% of its workSafety Research: 0 fractional works · 0.4% of its workSociology and Political Science: 0 fractional works · 0.2% of its workCultural Studies: 0 fractional works · 0.2% of its workDevelopment: 0 fractional works · 0.2% of its workPolitical Science and International Relations: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 1 fractional works · 0.9% of its workEconomics and Econometrics: 1 fractional works · 0.9% of its workPsychology: 1 fractional works · 0.7% of its workClinical Psychology: 1 fractional works · 0.7% of its workBusiness, Management and Accounting: 0 fractional works · 0.5% of its workManagement of Technology and Innovation: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workArts and Humanities: 0 fractional works · 0.4% of its workLanguage and Linguistics: 0 fractional works · 0.4% of its workDecision Sciences: 0 fractional works · 0.1% of its workALL ITS WORKSouth TexasAccelerated…78fractional works, 2022-now
Life Sciences29%Physical Sciences5%Health Sciences61%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 22 fields, with their numbers
    1. Medicine4760.4%
    2. Health Professions10.8%
    3. Nursing00.1%
    4. Dentistry00.0%
    1. Biochemistry, Genetics and Molecular Biology1621.0%
    2. Immunology and Microbiology56.6%
    3. Agricultural and Biological Sciences10.7%
    4. Neuroscience00.5%
    5. Pharmacology, Toxicology and Pharmaceutics00.3%
    1. Engineering22.4%
    2. Physics and Astronomy11.3%
    3. Computer Science00.5%
    4. Materials Science00.4%
    5. Chemistry00.2%
    6. Mathematics00.1%
    7. Environmental Science00.1%
    1. Social Sciences22.1%
    2. Economics, Econometrics and Finance10.9%
    3. Psychology10.7%
    4. Business, Management and Accounting00.5%
    5. Arts and Humanities00.4%
    6. Decision Sciences00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.15× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.94× its world share, 16 worksBiochemistry, Geneti…Immunology and Microbiology: 6.55× its world share, 5 worksImmunology and Micro…Neuroscience: 0.32× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 0.92× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.15× its world share, 0 worksChemistryComputer Science: 0.06× its world share, 0 worksComputer ScienceEngineering: 0.16× its world share, 2 worksEngineeringEnvironmental Science: 0.01× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.12× its world share, 0 worksMaterials ScienceMathematics: 0.06× its world share, 0 worksMathematicsPhysics and Astronomy: 0.58× its world share, 1 worksPhysics and AstronomyDentistry: 0.05× its world share, 0 worksDentistryHealth Professions: 0.31× its world share, 1 worksHealth ProfessionsMedicine: 3.14× its world share, 47 worksMedicineNursing: 0.14× its world share, 0 worksNursingArts and Humanities: 0.15× its world share, 0 worksArts and HumanitiesBusiness, Management and Accounting: 0.14× its world share, 0 worksBusiness, Management…Decision Sciences: 0.07× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 0.41× its world share, 1 worksEconomics, Econometr…Psychology: 0.22× its world share, 0 worksPsychologySocial Sciences: 0.16× its world share, 2 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.5×. Every wedge is a field page.

All 22 fields, with their numbers
  1. Immunology and Microbiology6.55×5 works
  2. Biochemistry, Genetics and Molecular Biology3.94×16 works
  3. Medicine3.14×47 works
  4. Pharmacology, Toxicology and Pharmaceutics0.92×0 works
  5. Physics and Astronomy0.58×1 works
  6. Economics, Econometrics and Finance0.41×1 works
  7. Neuroscience0.32×0 works
  8. Health Professions0.31×1 works
  9. Psychology0.22×0 works
  10. Engineering0.16×2 works
  11. Social Sciences0.16×2 works
  12. Agricultural and Biological Sciences0.15×0 works
  13. Chemistry0.15×0 works
  14. Arts and Humanities0.15×0 works
  15. Nursing0.14×0 works
  16. Business, Management and Accounting0.14×0 works
  17. Materials Science0.12×0 works
  18. Decision Sciences0.07×0 works
  19. Computer Science0.06×0 works
  20. Mathematics0.06×0 works
  21. Dentistry0.05×0 works
  22. Environmental Science0.01×0 works

Who are the top researchers at South Texas Accelerated Research Therapeutics?

Ranked on the quality score, Amita Patnaik, Kyriakos P. Papadopoulos and Anthony W. Tolcher lead among researchers whose main affiliation is South Texas Accelerated Research Therapeutics.

  1. 1 Amita Patnaik United States · #34,782 worldwide 36k citations · 739 works
  2. 2 Kyriakos P. Papadopoulos United States · #39,598 worldwide 18k citations · 763 works
  3. 3 Anthony W. Tolcher United States · #88,271 worldwide 25k citations · 945 works
  4. 4 Drew Warren Rasco United States · #90,188 worldwide 8.7k citations · 466 works
  5. 5 Muralidhar Beeram United States · #169,526 worldwide 7k citations · 170 works
  6. 6 Michael J. Wick United States · #278,694 worldwide 3.8k citations · 298 works
  7. 7 Nehal J. Lakhani United States · #329,869 worldwide 4.8k citations · 310 works
  8. 8 Sreenivasa Rao Chandana United States · #660,826 worldwide 3.2k citations · 119 works
  9. 9 Lon S. Smith United States · #921,338 worldwide 3.9k citations · 70 works
  10. 10 Alyssa D. Moriarty United States · #959,433 worldwide 579 citations · 62 works
All ranked researchers at South Texas Accelerated Research Therapeutics

What are the most cited papers from South Texas Accelerated Research Therapeutics?

The most cited paper from South Texas Accelerated Research Therapeutics is "Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer" (Edward B. Garon et al., 2015), with 6,312 citations. Next come "Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma" (3,425) and "Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children" (2,827).

Most cited papers
#PaperReleasedCitations
1 Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon et al. · New England Journal of Medicine Open access 19 Apr 2015 6,312
2 Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid et al. · New England Journal of Medicine Open access 2 Jun 2013 3,425
3 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 21 Feb 2018 2,827
4 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi et al. · Nature Open access 21 Mar 2010 2,506
5 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert et al. · The Lancet 14 Jul 2014 1,779
All 60 most cited papers, with filters and sorting

Which keywords describe research at South Texas Accelerated Research Therapeutics?

By fractional works in 2022-now, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Immunotherapy, Tumor Microenvironment, Targeted Therapy, Metastatic Breast Cancer, Clinical Trials and Cell Cycle Control.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy11▲ 19×14 topics
  2. Breast Cancer10▲ 53×6 topics
  3. Immunotherapy9▲ 17×14 topics
  4. Tumor Microenvironment7▲ 20×8 topics
  5. Targeted Therapy7▲ 40×5 topics
  6. Metastatic Breast Cancer6▲ 130×2 topics
  7. Clinical Trials6▲ 11×7 topics
  8. Cancer5▲ 4.8×22 topics
  9. Cancer Therapy5▲ 10×14 topics
  10. Cell Cycle Control5▲ 175×2 topics
  11. Metastatic5▲ 90×2 topics
  12. CDK4/6 Inhibitors5▲ 207×1 topic
  13. Palbociclib5▲ 207×1 topic
  14. Cancer Immunotherapy4▲ 38×3 topics
  15. HER24▲ 176×1 topic
  16. Immune Checkpoint Blockade4▲ 49×1 topic
  17. PD-1 and PD-L14▲ 49×1 topic
  18. Trastuzumab4▲ 112×1 topic
  19. Tumor Regression4▲ 47×2 topics
  20. Genomic Profiling4▲ 48×2 topics
  21. Monoclonal Antibodies4▲ 54×3 topics
  22. Glycosylation4▲ 42×2 topics
  23. Therapeutic Antibodies4▲ 65×2 topics
  24. Antibody Engineering4▲ 81×1 topic
  25. Fc Receptors4▲ 81×1 topic
  26. Biomarkers3▲ 6.0×4 topics
  27. Molecular Subtypes3▲ 46×2 topics
  28. Prognostic Factors3▲ 9.0×12 topics
  29. PET Imaging3▲ 20×4 topics
  30. Genetic Mutations3▲ 7.6×11 topics
  31. Immunity2▲ 7.9×6 topics
  32. Transcriptional Regulation2▲ 19×7 topics
  33. Resistance Mechanisms2▲ 36×2 topics
  34. Treatment Guidelines2▲ 14×3 topics
  35. ALK Inhibitors2▲ 48×1 topic
  36. EGFR Mutations2▲ 48×1 topic
  37. Gene Therapy2▲ 15×4 topics
  38. Lymphoma2▲ 19×2 topics
  39. Metastasis2▲ 8.6×8 topics
  40. Tumor Targeting2▲ 16×3 topics

Which research topics does South Texas Accelerated Research Therapeutics publish most on?

By volume in 2022-now: Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers and Monoclonal and Polyclonal Antibodies Research.

  1. 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 5 works
  2. 2 HER2/EGFR in Cancer Research Oncology 4 works
  3. 3 Cancer Immunotherapy and Biomarkers Oncology 4 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 4 works
  5. 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
  6. 6 CAR-T cell therapy research Oncology 2 works
  7. 7 Cancer Research and Treatments Biotechnology 2 works
  8. 8 Colorectal Cancer Treatments and Studies Oncology 2 works
  9. 9 Cancer Genomics and Diagnostics Cancer Research 2 works
  10. 10 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 2 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available28.7%not open71.3%

World: 40% of research is openly available.

with international co-authors35.1%domestic only64.9%

World: 18% is written across borders.

How has South Texas Accelerated Research Therapeutics's research output changed?

Output in 2022-2025 was 9% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is South Texas Accelerated Research Therapeutics as a percentage of every work published that year, 0.00032% in 2024.

still counting0.00020%0.00040%0.00060%South Texas Accelerated Research Therapeutics0.00024% in 202519801990200020102020

Fractional works of South Texas Accelerated Research Therapeutics over all fractional works that year. How the balance of science has shifted.

Other research institutions in San Antonio

All research institutions in San Antonio

Share South Texas Accelerated Research Therapeutics's ranking

South Texas Accelerated Research Therapeutics on Science Explorer

A card with South Texas Accelerated Research Therapeutics's standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about South Texas Accelerated Research Therapeutics. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.